

1 **Original Article**

2

3 **High-Risk Endometrial Cancer Assessed by Immediate Intraoperative Frozen Sections of**  
4 **Sentinel Lymph Nodes – A Retrospective Study**

5

6 Sarah E Miller, MD<sup>1\*</sup>, Mahkam Tavallaei, MD<sup>2\*</sup>, Malte Renz, MD, PhD<sup>1\*</sup>, Ann K Folkins, MD<sup>3</sup>,

7 Amer Karam, MD.<sup>1#</sup>

8

9

10

11

12

13

14 # corresponding author

15 \* contributed equally

16

17 1: Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Stanford  
18 University School of Medicine

19 2: Division of Obstetrics & Gynecology, UCSF Fresno

20 3: Department of Pathology, Stanford University School of Medicine

21

22 Division of Gynecologic Oncology

23 Department of Obstetrics and Gynecology

24 300 Pasteur Drive, H 302

25 Stanford University School of Medicine

26 Stanford, CA 94305

27 P: 650-724-0456

28 F: 650-736-0902

29 Email: amkaram@stanford.edu

30

31 IRB Protocol Number: IRB-41259

32

33 Disclosure: The authors have nothing to disclose.

34

35 Keywords: sentinel lymph nodes, high-grade endometrial cancer

36 Word Count: 1533

37 **Highlights**

- 38 • Intraoperative SLN assessment in high-grade endometrial cancer by frozen section.
- 39 • 100% sensitivity and 0% false-negative rate compared to complete lymphadenectomy.
- 40 • Protocol provides immediate intraoperative feedback on successful SLN mapping.
- 41 • Protocol helps inform surgeon's decision to proceed with complete lymphadenectomy.

42

43

44

45

46

47 **Declarations**

48 Funding: there are no sources of funding to disclose

49 Conflicts of interest/Competing interests: Sarah Miller, MD, Mahkam Tavallaee, MD, Malte

50 Renz, MD, PhD, Ann K Folkins, MD and Amer Karam, MD declare that they have no conflict of  
51 interest

52 Ethics approval: Protocol Number IRB-41259

53 Consent to participate: not applicable

54 Consent for publication: not applicable

55 Availability of data and material: The authors confirm that the data supporting the findings of  
56 this study are available within the article [and/or] its supplementary material.

57 Code availability: not applicable

58 Authors' contributions: Conceptualization and Methodology: Dr. Amer Karam, Dr. Malte Renz,

59 and Dr. Ann Folkins; Formal Analysis and Investigation: Dr. Sarah Miller, Dr. Mahkam

60 Tavallaee, Dr. Ann Folkins, Dr. Malte Renz; Writing, reviewing and editing: Dr. Sarah Miller, Dr.

61 Mahkam Tavallaee, Dr. Malte Renz, Dr. Ann Folkins, Dr. Amer Karam

62 **Abstract**

63 While sentinel lymph node (SLN) sampling has been established for low-risk endometrial  
64 cancer, few data exists on high-risk histologies. This study aims to measure the accuracy of  
65 immediate intraoperative SLN biopsy with frozen section in high-risk endometrial cancer.

66 Patients diagnosed with endometrial cancer of high-grade histology (grade 3 endometrioid, clear  
67 cell, serous, carcinosarcoma, de- or undifferentiated histology) between 2014 and 2019 at a  
68 single institution who underwent SLN mapping, followed by pelvic lymphadenectomy with or  
69 without para-aortic lymphadenectomy were included. SLNs were assessed intraoperatively  
70 using multiple frozen sections and H&E staining. Lymph node metastases detected by SLN  
71 biopsy were compared with complete lymphadenectomy specimens.

72 35 patients with high-grade endometrial cancer histology underwent SLN mapping followed by  
73 lymphadenectomy. In 34 of 35 (97%) of these patients mapping with at least one SLN was  
74 successful. Positive SLNs were identified in 7/34 patients (20.6%). There were no patients who  
75 had positive lymph nodes on complete lymphadenectomy without a positive SLN, resulting in  
76 100% sensitivity, and 0% false-negative rate.

77 SLN mapping using intraoperative frozen sections in high-risk endometrial cancer demonstrated  
78 100% sensitivity and 0% false-negative rate, provides immediate feedback on successful SLN  
79 mapping and valuable intraoperative information on the disease status guiding the  
80 intraoperative decision for completion lymphadenectomy.

81

82

83

84

85

86

87

## 88 **Introduction**

89 In 1987, the GOG 33 trial results defined risk factors of extra-uterine spread, specifically lymph  
90 node metastases, for clinically uterine confined endometrial cancers [1]. Subsequently, in 1988,  
91 the FIGO staging for endometrial cancer was revised from a clinical staging to a surgical staging  
92 system that includes surgical lymph node assessment [2]. Randomized control trials, however,  
93 did not show any progression-free or overall survival benefit from complete lymphadenectomy in  
94 clinically early-stage uterine cancer [3, 4]. Sentinel lymph node injection and biopsy was  
95 introduced in order to reduce surgical morbidity associated with lymphadenectomy, particularly  
96 leg lymphedema, while maintaining the prognostic information gained from surgical staging and  
97 help guide adjuvant treatment decisions. While sentinel lymph node injection and biopsy has  
98 become an accepted approach for low-risk endometrial cancer, little data exists on endometrial  
99 cancer of high-risk histologies [5]. As per NCCN guidelines, sentinel lymph node injection and  
100 mapping may be used for high-risk histologies as well. These guidelines also state that sentinel  
101 lymph nodes should be processed using ultrastaging which includes serial sectioning and  
102 cytokeratin immunohistochemistry but standard protocols are not available [6]. In addition, the  
103 clinical significance of isolated tumor cells (ITC) defined as tumor deposits  $\leq 0.2$  mm and  $\leq 200$   
104 tumor cells remains uncertain.

105 Previously published retrospective analyses of high-risk endometrial cancer patients have  
106 reported on sentinel lymph node injection and mapping combined with ultrastaging and  
107 immunohistochemistry. The reported false-negative rates range from 4.2% to 22% [7-11]. We  
108 report the application of our previously published protocol for immediate intraoperative sentinel  
109 lymph node assessment by frozen section [12] for high-risk endometrial cancers. In high-risk  
110 endometrial cancer the immediate intraoperative feedback on successful SLN mapping and the  
111 disease status is especially important and may guide the intraoperative decision for a  
112 completion lymphadenectomy.

113

## 114 **Material and Methods**

### 115 **Patients**

116 Electronic medical records from 2014 to 2019 were reviewed, and consecutive patients with  
117 high-grade endometrial cancer (grade 3 endometrioid, clear cell, serous, carcinosarcoma, de- or  
118 undifferentiated histology) were evaluated for inclusion. Inclusion criteria were: high-grade  
119 histology on final pathology of the hysterectomy specimen, age older than 18 years, patients  
120 who underwent SLN injection and mapping followed by complete lymphadenectomy. The study  
121 was approved by our Institutional Review Board (IRB).

### 122 **Procedure**

123 Following successful induction of anesthesia, the cervix was injected in four quadrants with 0.5  
124 mL of a 0.5 mg/ mL indocyanine green solution. The Intuitive da Vinci Si or Xi surgical robotic  
125 systems were used for all robotic-assisted laparoscopic surgeries. Efferent lymphatic vessels  
126 and sentinel lymph nodes were visualized using near-infrared imaging, and sentinel lymph  
127 nodes were sent to pathology for intraoperative evaluation via frozen section. Subsequent  
128 complete pelvic lymphadenectomy was then performed according to the Gynecologic Oncology  
129 Group surgical handbook [13]. In agreement with current NCCN guidelines, para-aortic lymph  
130 node dissection was performed when risk factors were identified and at the discretion of the  
131 physician. The study was IRB approved and patients were consented for sentinel lymph node  
132 injection and biopsy and lymph node dissection.

### 133 **Pathology**

134 Following dissection and removal, sentinel lymph nodes sent for intraoperative analysis were  
135 either partially or entirely submitted for microscopic examination at the discretion of the  
136 pathologist. Lymph nodes that were partially submitted were assessed intraoperatively by  
137 evaluating 2 hematoxylin and eosin (H&E) stained sections, with additional permanent sections  
138 (2-4) evaluated post-operatively. In contrast, entirely submitted lymph nodes were solely  
139 assessed intraoperatively by evaluating 4 or more H&E stained sections at levels evenly

140 distributed levels in the tissue block. A lymph node metastasis was defined as the presence of  
141 tumors cells of any number or size ranging from isolated tumor cells to macro-metastases.

## 142 **Statistics**

143 Successful sentinel lymph node mapping was calculated as the number of patients with at least  
144 one detected SLN divided by the total number of patients who underwent mapping. We also  
145 calculated the rate of bilateral sentinel lymph node mapping. False negative cases were defined  
146 as patients whose sentinel lymph node sampling was negative for disease but who had disease  
147 detected on subsequent pelvic lymphadenectomy. Risk factors for sentinel and non-sentinel  
148 lymph node metastases were evaluated using Fisher's Exact test. A p-value of < 0.05 was  
149 considered statistically significant. Data regarding intraoperative and postoperative  
150 complications, such as urinary and nerve injuries as well as lymphoceles and lymphedema, was  
151 derived from operative reports and postoperative follow up notes.

152

## 153 **Results**

154 Between April 2014 and September 2019, 35 patients with high-risk endometrial cancer  
155 underwent sentinel lymph node injection and sampling followed by complete lymphadenectomy  
156 by one surgeon at Stanford University. The mean age was 66 +/- 9 years and the mean body  
157 mass index 29 +/- 2 kg/m<sup>2</sup>.

158 Final pathological diagnosis and FIGO stage of the 36 patients are outlined in Table 1. 27 out of  
159 35 patients (77%) had endometrial cancers confined to the uterus on final pathology (Stage IA  
160 or IB).

161 In 34 of the 35 patients (97%), at least one lymph node was successfully mapped (Table 2). In  
162 26 of the 35 patients (74%), bilateral mapping was successful. While complete pelvic  
163 lymphadenectomy was done in all patients, para-aortic lymphadenectomy was concurrently  
164 performed in 21 out of 35 patients (60%). The median number of sentinel nodes removed was 2

165 (0-13) and the mean number of total nodes removed during complete lymphadenectomy was 24  
166 +/- 10.

167 Table 3 shows the total number of sentinel lymph nodes successfully mapped and the number  
168 of positive sentinel lymph nodes in this series. 118 nodes were successfully identified and  
169 removed; 63 from the right side and 55 from the left. Predominant locations of the detected  
170 sentinel lymph nodes were in the external iliac area with 58.5% (69/118) and the obturator  
171 space with 36.4% (43/118). In this series, no isolated para-aortic sentinel lymph nodes were  
172 detected.

173 Sensitivity and specificity data were calculated from the 34 patients in which at least one  
174 sentinel lymph node was successfully mapped (Table 4). Both, sensitivity and specificity were  
175 100%. No false-negative sentinel lymph nodes were detected. 7 out 34 patients (20.6%)  
176 showed positive sentinel lymph nodes. 3 out of the 7 patients (42.8%) with positive sentinel  
177 lymph nodes also had positive non-sentinel lymph nodes. All 3 patients with positive sentinel  
178 and non-sentinel lymph nodes had positive para-aortic non-sentinel lymph nodes as well. In one  
179 patient, the para-aortic non-sentinel lymph nodes were positive even in the absence of positive  
180 pelvic non-sentinel lymph nodes. Clinical and histological characteristics and anatomical  
181 locations of the positive sentinel lymph nodes are described in Supplementary Table 1 and 2.  
182 Table 5 displays risk factors associated with lymph node metastases. In this series, a  
183 statistically significant correlation was noted between lymph node metastases and  
184 lymphovascular space invasion ( $p=0.0059$ ), depth of myometrial invasion ( $p=0.0238$ ), and age  
185 ( $p=0.0238$ ).

186 No ureteral injuries were noted. 3/35 (9%) patients experienced numbness along the distribution  
187 of the genitofemoral nerve were noted which all resolved on follow up. 5/35 asymptomatic  
188 lymphoceles were observed that did not require any further intervention. 8/35 (23%) of the  
189 patients developed symptomatic lymphedema of the lower extremities.

190

191 **Discussion**

192 This study presents a single-surgeon, single-institution experience using a protocol of  
193 immediate intraoperative assessment of sentinel lymph nodes by frozen section [12]. Our  
194 results demonstrate 100% sensitivity and 0% false-negative rate using this protocol for high-risk  
195 endometrial histologies and add to the growing evidence supporting SLN injection and biopsy as  
196 substitute for routine complete lymphadenectomy in this patient population [7-11]. Our series  
197 confirms the accuracy of our previously published protocol for immediate intraoperative  
198 assessment of sentinel lymph node by frozen section in detecting sentinel lymph node  
199 metastases. The accuracy of this protocol is essential for high-risk endometrial cancers where  
200 the rate of lymph node metastases is elevated; here, we report a 20.6% sentinel lymph node  
201 positivity rate compared to 7.6% in our previous series which comprised predominantly low-risk  
202 endometrial cancers.

203 Metastatic non-sentinel lymph nodes were found in about 40% of our patients with positive  
204 sentinel lymph nodes, all of which included positive para-aortic non-sentinel lymph nodes. In the  
205 current NCCN guidelines, para-aortic lymph node dissection in endometrial cancers is left up to  
206 the discretion of the attending surgeon with little data to support this decision, particularly in  
207 high-risk histologies [14].

208 In vulvar cancer, a completion lymphadenectomy is recommended once macro-metastatic  
209 disease is discovered in a sentinel lymph node [15]. In breast cancer, it is recommended to  
210 perform a completion axillary lymphadenectomy when more than 2 sentinel lymph nodes are  
211 involved or no radiation planned [16, 17]. For high-risk endometrial cancers, however, similar  
212 recommendations do not exist. Randomized trials examining the utility of lymphadenectomy in  
213 endometrial cancer included mostly patients with low-risk and few with high-risk histologies [3,  
214 4]. Several retrospective studies denote a survival benefit from completion lymphadenectomy in  
215 high-grade histologies [18-20]. Intraoperative frozen section may help determine which patients  
216 benefit from completion lymphadenectomy at the time of original surgery as well as confirm the



217 presence of lymph node tissue in the specimen [12, 21] thus avoiding the potential morbidity of  
218 additional surgery as well as incomplete prognostic information.

219 The limitations of this study are that this series is a small retrospective single-surgeon and  
220 single-institutional study. Also, intraoperative assessment of sentinel lymph node protocol by  
221 frozen section may not be universally feasible or reproducible.

## 222 **Conclusion**

223 In summary, we determined that our intraoperative SLN protocol shows 100% sensitivity and  
224 0% false negative rate. Intraoperative SLN assessment in high-risk endometrial cancers  
225 provides immediate feedback on the success of SLN mapping and may help inform the  
226 surgeon's decision whether to proceed with a complete lymph node dissection including pelvic  
227 and para-aortic lymph nodes.

228

229

230 Compliance with Ethical Standards:

231 Conflict of Interest: The authors declare that they have no conflict of interest.

232 Ethical approval: All procedures performed in studies involving human participants were in

233 accordance with the ethical standards of the institutional and/or national research committee

234 and with the 1964 Helsinki declaration and its later amendments or comparable ethical

235 standards. Informed consent was obtained from all individual participants included in the study.

236 **References:**

- 237 1. Creasman, W.T., et al., *Surgical pathologic spread patterns of endometrial cancer. A*  
238 *Gynecologic Oncology Group Study*. Cancer, 1987. **60**(8 Suppl): p. 2035-41.
- 239 2. Mikuta, J.J., *International Federation of Gynecology and Obstetrics staging of*  
240 *endometrial cancer 1988*. Cancer, 1993. **71**(4 Suppl): p. 1460-3.
- 241 3. Benedetti Panici, P., et al., *Systematic pelvic lymphadenectomy vs. no*  
242 *lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial*. J Natl  
243 Cancer Inst, 2008. **100**(23): p. 1707-16.
- 244 4. group, A.s., et al., *Efficacy of systematic pelvic lymphadenectomy in endometrial cancer*  
245 *(MRC ASTEC trial): a randomised study*. Lancet, 2009. **373**(9658): p. 125-36.
- 246 5. Holloway, R.W., et al., *Sentinel lymph node mapping and staging in endometrial cancer:*  
247 *A Society of Gynecologic Oncology literature review with consensus recommendations*.  
248 Gynecol Oncol, 2017. **146**(2): p. 405-415.
- 249 6. Renz, M., et al., *Sentinel lymph node biopsies in endometrial cancer - practice patterns*  
250 *among Gynecologic Oncologists in the United States*. J Minim Invasive Gynecol, 2019.
- 251 7. Papadia, A., et al., *Retrospective validation of the laparoscopic ICG SLN mapping in*  
252 *patients with grade 3 endometrial cancer*. J Cancer Res Clin Oncol, 2018. **144**(7): p.  
253 1385-1393.
- 254 8. Touhami, O., et al., *Performance of sentinel lymph node (SLN) mapping in high-risk*  
255 *endometrial cancer*. Gynecol Oncol, 2017. **147**(3): p. 549-553.
- 256 9. Tanner, E.J., et al., *The Utility of Sentinel Lymph Node Mapping in High-Grade*  
257 *Endometrial Cancer*. Int J Gynecol Cancer, 2017. **27**(7): p. 1416-1421.
- 258 10. Soliman, P.T., et al., *A prospective validation study of sentinel lymph node mapping for*  
259 *high-risk endometrial cancer*. Gynecol Oncol, 2017. **146**(2): p. 234-239.
- 260 11. Ehrisman, J., et al., *Performance of sentinel lymph node biopsy in high-risk endometrial*  
261 *cancer*. Gynecol Oncol Rep, 2016. **17**: p. 69-71.
- 262 12. Renz, M., et al., *Immediate intraoperative sentinel lymph node analysis by frozen section*  
263 *is predictive of lymph node metastasis in endometrial cancer*. J Robot Surg, 2019.
- 264 13. Group, G.O., *Surgical Procedures Manual*. [www.gogmember.gog.org](http://www.gogmember.gog.org), revised 2005.
- 265 14. Network, N.C.C., *NCCN Clinical Practice Guidelines in Oncology - Uterine Neoplasms*.  
266 2020.
- 267 15. (NCCN), N.C.C.N., *NCCN Clinical Practice Guidelines in Oncology - Vulvar Cancer*  
268 *(Squamous Cell Carcinoma)*. 2020.
- 269 16. Giuliano, A.E., et al., *Locoregional recurrence after sentinel lymph node dissection with*  
270 *or without axillary dissection in patients with sentinel lymph node metastases: the*  
271 *American College of Surgeons Oncology Group Z0011 randomized trial*. Ann Surg,  
272 2010. **252**(3): p. 426-32; discussion 432-3.
- 273 17. Network, N.C.C., *NCCN Clinical Practice Guidelines in Oncology - Breast Cancer*. 2020.
- 274 18. Mahdi, H., et al., *Prognostic impact of lymphadenectomy in uterine serous cancer*.  
275 BJOG, 2013. **120**(4): p. 384-91.
- 276 19. Mahdi, H., D. Lockhart, and M. Moselmi-Kebria, *Prognostic impact of lymphadenectomy*  
277 *in uterine clear cell carcinoma*. J Gynecol Oncol, 2015. **26**(2): p. 134-40.
- 278 20. Todo, Y., et al., *Survival effect of para-aortic lymphadenectomy in endometrial cancer*  
279 *(SEPAL study): a retrospective cohort analysis*. Lancet, 2010. **375**(9721): p. 1165-72.
- 280 21. Casarin, J., et al., *Frozen Section for Detection of Lymph Nodes After Cervical Injection*  
281 *with Indocyanine Green (ICG) for Sentinel Lymph Node Technique in Endometrial*  
282 *Cancer Staging*. Ann Surg Oncol, 2018. **25**(12): p. 3692-3698.
- 283

284

285 **Figures and Tables:**

286 **Table 1:** Pathological features and postoperative stage of the 35 patients who received  
287 complete study intervention, i.e. injection of dye, attempted sentinel lymph node mapping and  
288 complete surgical staging. Data are median (range) or n (%).

289 **Table 2:** Surgical results in patients with lymphadenectomy of the 35 patients who received  
290 complete study intervention, i.e. injection of dye, attempted sentinel lymph node mapping and  
291 complete surgical staging. Data are n (%) or median (range).

292 **Table 3:** Numbers and locations of positive SLN/successfully mapped SLN.

293 **Table 4:** 2x2 table providing sensitivity and specificity data.

294 **Table 5:** Risk factors for lymph node metastasis. P-values for chi-square analysis were  
295 calculated using Fisher's exact test for 2 x 2 tables with two-tailed significance set to  $p < 0.05$ .

296

297 **Suppl. Table 1:** Clinical and histological characteristics of patients with positive SLN and post-  
298 operative complications. BMI = body mass index, LN = lymph node, LVSI = lymphovascular  
299 space invasion, HG = High Grade

300 **Suppl. Table 2:** Anatomical location of positive SLNs. NSLN, non-sentinel lymph node; SLN,  
301 sentinel lymph node; REI, right external iliac; LEI, left external iliac; RO, right obturator; LO, left  
302 obturator.

303

304 **Table 1: Patient demographics, tumor characteristics, pathologic features and**  
 305 **postoperative stage**

<b>Demographics</b>	<b>median (range)</b>
Age (years)	67 (46-87)
BMI	30 (18-44)
<b>Tumor Characteristics</b>	<b>median (range)</b>
Mean tumor size (mm)	39 (0-78)
Mean depth of invasion (%)	38 (0-100)
<b>Lymphovascular space invasion (LVSI)</b>	
LVSI present	13/35 (37%)
<b>Pathologic Features</b>	
Grade 3 Endometrial Carcinoma	11/35 (32%)
Uterine Serous Carcinoma	11/35 (32%)
Clear Cell Carcinoma	1/35 (3%)
Uterine Carcinosarcoma	8/35 (23%)
Un-/de- or poorly differentiated carcinoma	4/35 (11%)
<b>FIGO Stage</b>	
IA	22/35 (63%)
IB	5/35 (14%)
II	1/35 (3%)
IIIA	0/35 (0%)
IIIB	1/35 (3%)
IIIC1	3/35 (9%)
IIIC2	3/35 (9%)
IV	0/35 (0%)

306

307 **Table 2: Surgical results and complications in patients with lymphadenectomy**

	<b>n = 35</b>
<b>Surgical results</b>	
Pelvic lymphadenectomy	35/35 (100%)
Pelvic and para-aortic lymphadenectomy	21/35 (60%)
Successful at least unilateral sentinel lymph node mapping	34/35 (97%)
Successful bilateral sentinel lymph node mapping	26/35 (74%)
Para-aortic sentinel lymph nodes detected	1/35 (3%)
Isolated para-aortic sentinel lymph nodes	0/35 (0%)
<b>Nodes removed</b>	<b>median (range)</b>
Median number of sentinel lymph nodes removed	2 (0-13)
Median number of total nodes removed	22 (13-55)
<b>Complications</b>	
Post-operative lymphocyst	8/35 (23%)
Post-operative lymphedema	8/35 (23%)

308

309 **Table 3: Numbers of positive SLN/successfully mapped SLN**

<b>SLN site</b>	
Right Para-aortic	0/1
Right common iliac	0/4
Right external iliac	3/35
Left external iliac	2/34
Right obturator	4/22
Left obturator	1/21
Right parametrial	0/1

310

311 **Table 4: Sensitivity and specificity data**

	<b>True Positive Nodes</b>	<b>True Negative Nodes</b>	
<b>Positive SLN</b>	7	0	PPV 7/7 (100%)
<b>Negative SLN</b>	0	27	NPV 27/27 (100%)
	Sn 7/7 (100%)	Sp 27/27 (100%)	ACC 34/34 (100%)
	FNR 0/7 (0%)	FPR 0/27 (0%)	

312 Sn = Sensitivity, Sp = Specificity, FNR = False Negative Rate, FPR = False Positive Rate, PPV = Positive Predictive Value, NPV = Negative Predictive Value, ACC = Accuracy



313 **Table 5: Risk factors for lymph node metastasis**

<b>Characteristic</b>	<b>Node Negative</b>	<b>Node Positive</b>	<b>p-value</b>
<b>Tumor Size</b>			
<2cm	6	0	.3058
≥2cm	21	7	
<b>Lymphovascular Space Invasion</b>			
Absent	21	1	<b>.0059</b>
Present	7	6	
<b>Lower Uterine Segment Involvement</b>			
Absent	18	3	.4007
Present	10	4	
<b>Depth of Myometrial Invasion</b>			
None and <50%	21	2	<b>.0238</b>
≥50%	6	5	
<b>Age</b>			
<70	21	2	<b>.0238</b>
≥70	6	5	

314

315 **Suppl. Table 1:** Clinical and histological characteristics of patients with positive SLN and post-  
 316 operative complications

	Age Range	BMI (kg/m <sup>2</sup> )	Diagnosis	Final Grade	Tumor Size (cm)	Size of Largest LN Met (mm)	Myometrial Invasion mm/mm (%)	LVSI	TMN Stage	FIGO Stage	Lymph-edema	Lymphocyst
1	70-75	33	Carcinosarcoma	N/A	2.4	2.0	N/A	No	pT1a pN1	IIIC1	No	No
2	70-75	24	Clear Cell	N/A	2.5	15.0	8.5/9 (94%)	Yes	pT1b pN2	IIIC2	Yes	Yes
3	70-75	29	Serous	HG	6.0	7.0	7/11 (64%)	Yes	pT2 pN2a	IIIC2	No	No
4	60-65	27	Endometrial Adenocarcinoma	3	7.5	2.0	17/17 (100%)	Yes	pT3b pN1a	IIIC1	Yes	No
5	55-60	29.6	Carcinosarcoma	N/A	7.8	7.0	9/11 (82%)	Yes	pT3a pN2a	IIIC2	No	No
6	70-75	26	Serous	HG	7.2	10.0	10/10.5 (95%)	Yes	pT3a pN1a	IIIC1	No	Yes
7	75-80	22	Carcinosarcoma	N/A	6.0	0.5	0.6/11.5 (5%)	Yes	pT1a pN1mi	IA	No	No

317

BMI = body mass index, LN = lymph node, LVSI = lymphovascular space invasion, HG = High Grade

318 **Suppl. Table 2:** Anatomical location of positive SLNs  
 319

	Right			Left			Total LN	+SLN sites
	Pelvic NSLN	PA NSLN	SLN	Pelvic NSLN	PA NSLN	SLN		
1	0/12	0/0	1/5	0/13	0/0	0/2	1/32	REI
2	0/7	1/3	0/0	0/7	2/14	1/1	4/32	LEI
3	1/14	0/3	1/1	0/22	2/4	0/0	4/44	REI
4	0/8	0/3	2/3	0/6	0/4	1/3	3/27	LO, RO, RO
5	0/6	0/5	1/2	1/8	1/2	0/0	3/23	RO
6	0/6	0/2	1/2	0/10	0/1	1/2	4/23	LEI, RO
7	0/8	0/0	1/2	0/4	0/0	0/1	1/15	REI

320

321 NSLN = non-sentinel lymph node, PA = para-aortic, SLN = sentinel lymph node, REI = right external iliac, LEI = left external iliac, LO = left obturator, RO = right obturator